Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Total Liabilities (2016 - 2025)

Capricor Therapeutics has reported Total Liabilities over the past 15 years, most recently at $50.2 million for Q4 2025.

  • Quarterly results put Total Liabilities at $50.2 million for Q4 2025, up 100.48% from a year ago — trailing twelve months through Dec 2025 was $50.2 million (up 100.48% YoY), and the annual figure for FY2025 was $50.2 million, up 100.48%.
  • Total Liabilities for Q4 2025 was $50.2 million at Capricor Therapeutics, up from $42.6 million in the prior quarter.
  • Over the last five years, Total Liabilities for CAPR hit a ceiling of $50.2 million in Q4 2025 and a floor of $6.4 million in Q3 2021.
  • Median Total Liabilities over the past 5 years was $33.6 million (2023), compared with a mean of $30.4 million.
  • Biggest five-year swings in Total Liabilities: surged 504.94% in 2022 and later plummeted 38.14% in 2024.
  • Capricor Therapeutics' Total Liabilities stood at $10.0 million in 2021, then surged by 284.54% to $38.3 million in 2022, then decreased by 5.68% to $36.1 million in 2023, then crashed by 30.76% to $25.0 million in 2024, then skyrocketed by 100.48% to $50.2 million in 2025.
  • The last three reported values for Total Liabilities were $50.2 million (Q4 2025), $42.6 million (Q3 2025), and $28.6 million (Q2 2025) per Business Quant data.